Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00223223|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : August 3, 2011
The purpose of this research is to determine whether the memory impairment and manic symptoms (feelings of agitation, overexcitement or hyperactivity) typically seen in those on corticosteroid therapy is decreased with a seizure medication called levetiracetam compared to placebo (an inactive substance). Since increased levels of cortisol (the body's natural corticosteroid) in the body are frequently associated with memory impairment interventions that may prevent or reverse this are of great importance.
It is hypothesized that patients who are scheduled to receive prescription corticosteroid therapy who are given levetiracetam pretreatment will show lesser memory impairment and manic symptoms than those receiving placebo.
|Condition or disease||Intervention/treatment||Phase|
|Memory Loss Associated With Corticosteroid Use Manic State Associated With Corticosteroid Use||Drug: Levetiracetam, Keppra||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||November 2005|
|Study Completion Date :||November 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223223
|United States, Texas|
|The University of Texas Southwestern Medical Center|
|Dallas, Texas, United States, 75235|
|Principal Investigator:||E. Sherwood Brown, M.D., Ph.D.||UT Southwestern Medical Center at Dallas|